TP53 and pancreatic neuroendocrine tumor: However, more recent molecular studies of G3 pancreatic NET have demonstrated higher rates of TP53 alterations (10–38%), indicating that TP53 can be acquired in NET progression and p53 IHC may not reliably distinguish NEC from G3 NET [14, 25–27].